SCHEMBL30294796

SCHEMBL30294796

CCOC(=O)c1cc(Cl)ccc1Nc1ccc(F)cc1C

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
ALDH1A1 P00352 2/20 0.50
KMT2A Q03164 1/20 0.50
MRGPRX1 Q96LB2 2/20 0.47
TSHR P16473 1/20 0.44
MAPK13 O15264 1/20 0.44
MAPK12 P53778 1/20 0.44
MAPK11 Q15759 1/20 0.44
MAPK14 Q16539 1/20 0.44
METTL3 Q86U44 1/20 0.44
TDP1 Q9NUW8 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
POLB P06746 2/20 0.43
THRB P10828 1/20 0.43
TP53 P04637 1/20 0.43
LMNA P02545 2/20 0.43
KDM4E B2RXH2 1/20 0.43
CDC25B P30305 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22853357 1.00 MAPT (0.50) MAPTALDH1A1KMT2AMRGPRX1TSHR
SCHEMBL30294784 0.91 MAPT (0.49) MAPTALDH1A1KMT2AMRGPRX1TSHR
SCHEMBL22853397 0.91 MAPT (0.49) MAPTALDH1A1KMT2AMRGPRX1TSHR
SCHEMBL31521818 0.88 KMT2A (0.53) MAPTALDH1A1KMT2AMRGPRX1MAPK13
SCHEMBL30294266 0.87 SMN1; SMN2 (0.50) MAPTMRGPRX1TSHRTDP1SMN1; SMN2
SCHEMBL22853409 0.87 SMN1; SMN2 (0.50) MAPTMRGPRX1TSHRTDP1SMN1; SMN2
SCHEMBL22853077 0.87 MRGPRX1 (0.54) MAPTALDH1A1KMT2AMRGPRX1TSHR
SCHEMBL30294699 0.87 MRGPRX1 (0.54) MAPTALDH1A1KMT2AMRGPRX1TSHR
SCHEMBL22853414 0.83 MRGPRX4 (0.45) TSHRTDP1SMN1; SMN2POLBTHRB
SCHEMBL30294513 0.83 MRGPRX4 (0.45) TSHRTDP1SMN1; SMN2POLBTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B MAPT 215/4885ALDH1A1 3102/4885KMT2A 2375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.